Governance at a Glance

Chair
Member
Board Members Audit Compensation Nominating and Corporate Governance Business and Strategy ESG Succession Planning

Sergio Stevanato

Business and Strategy

Franco Stevanato

Nominating and Corporate Governance
Business and Strategy
Succession Planning

Madhavan Balachandran

Compensation
Business and Strategy
ESG
Succession Planning

Fabrizio Bonanni

Nominating and Corporate Governance
Business and Strategy
Succession Planning

Fabio Buttignon

Audit
ESG

William Federici

Audit
Business and Strategy

Karen Flynn

Business and Strategy
ESG

Donald Eugene Morel Jr.

Compensation
Nominating and Corporate Governance
Business and Strategy
Succession Planning

Franco Moro

Business and Strategy

Luciano Santel

Audit
Nominating and Corporate Governance
Business and Strategy

Alvise Spinazzi

Paola Vezzaro

Compensation
ESG
Succession Planning

Committee Charters

Sergio Stevanato

Sergio Stevanato

Son of Giovanni Stevanato, founder of the Stevanato Group, Sergio Stevanato has been actively involved in the family business since high school. He graduated in law from the University of Ferrara in 1969, to then take the leadership of the Company. He has dedicated his career to the family business of which he is currently the Emeritus Chairman. In 2007 he was awarded by the President of the Italian Republic the honorary recognition of Knight of Labor (Cavaliere del Lavoro) for his achievements as an entrepreneur.

Franco Stevanato

Franco Stevanato

Son of Sergio Stevanato, Franco Stevanato graduated in Political Science from the University of Trieste in 1998 and attended an Advanced Management Program at the Kellogg School of Management in 2015. During his university years, he gained professional experience in the sales department of Saint Gobain in France. Upon completing his studies, he joined the family business, initially taking up a role in sales. Over the years, he has been the key figure and driving force behind the long-term vision of Stevanato Group including the internationalization of the Company and its continuing development from product diversification to enhance managerial processes, drive continuous innovation, and structural improvements. He also contributed to improving the Stevanato Group’s corporate governance by building an effective infrastructure to support decision making and promoting a skills-based board that benefits from specialist expertise and meaningful perspective. Franco served as Chief Executive Officer from 2010 to 2020, and in 2021, he was appointed Executive Chairman of the Board.

Madhavan Balachandran

Madhavan Balachandran

Holding a master’s degree in Chemical Engineering from the State University of New York at Buffalo and an MBA from East Carolina University, Madhavan is Chief Operating Officer of Nutcracker Therapeutics, a developer of mRNA therapeutics, a position he has held since September 2020. He previously served as Chief Executive Officer of ADRx, Inc., a pre-clinical stage biotechnology company since August 2019. Prior to that, he was Executive Vice President, Operations of Amgen Inc. from August 2012 until July 2016 and retired as an Executive Vice President in January 2017, having served in various management positions since joining the company in 1997. Prior to his tenure at Amgen, Madhavan held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd. and Burroughs Welcome Company, a predecessor before mergers of GlaxoSmithKline plc. He currently serves as a director in Catalent Inc. and uniQure NV. He has been a member of the board of directors of Stevanato Group since 2018.

Fabrizio Bonanni

Fabrizio Bonanni

Holding a doctorate in chemistry from the University of Florence, Italy, Fabrizio carried out postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. He spent 25 years at Baxter International in Italy, Belgium, and the U.S. reaching the positions of corporate vice president Quality System and CVP Regulatory and Clinical Affairs. From 1999 to 2013, he served in senior executive roles at Amgen, including senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and executive vice president, Operations. Currently, he is a member of the board of INCOG BioPharma Services. His past board memberships include UCLA’s Technology Development Corporation, XBiotech, where he chaired the Audit Committee, Menarini Biotech, and Theranos, where he chaired the Compliance and Quality Committee. He has been a member of the board of directors of Stevanato Group since 2013.

Fabio Buttignon

Fabio Buttignon

Fabio Buttignon (Belluno, 1959) is full professor of Advanced Corporate Finance at the University of Padua. Graduated at Ca’ Foscari University of Venice, where he also worked as researcher and associate professor. He has studied and carried out research at the University of California in Los Angeles (UCLA). He is the author of numerous national and international publications on strategy, finance and company valuation. He is a Chartered Accountant (CPA) and Auditor. He participates in corporate governance in listed and unlisted companies. He is founder and managing partner of Buttignon Zotti Milan & Co., an independent advisory boutique specialized in valuation, mergers and acquisitions, capital raising and financial restructuring. He has been a member of the board of directors of Stevanato Group since 2014.

William Federici

William Federici

Holding a B.A. in Economics from Rutgers University, Livingston College and an MBA in Professional Accounting from Rutgers University, William is a member of the American Institute of Certified Public Accountants. He serves on the Board of Directors of Zynerba Pharmaceuticals, Inc., a Specialty Pharmaceutical, U.S. public company, where he has served as Audit Committee Board Chair since 2015. William joined West Pharmaceutical Services, Inc., in 2003 as Chief Financial Officer until his retirement in 2018. Prior to West, Bill spent more than 20 years’ experience in public accounting primarily serving the Pharmaceutical Industry. He has been a member of the board of directors of Stevanato Group in May 2021.

Karen Flynn

Karen Flynn

Karen Flynn has more than 35 years of experience in the pharmaceutical services industry. She retired in October 2023 from the position of President, Biomodalities at Catalent Pharma Solutions, a position she held since April 2023. Prior to this, she was Senior Vice President and Chief Commercial Officer at Catalent until September 2022. She joined Catalent as President, Biologics and Chief Commercial Officer in January 2020 and held that position until October 2021. Before Catalent, Ms. Flynn was Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services, Inc. from 2016 to 2019, and served as its President of Pharmaceutical Packaging Systems from 2014 and President of the Americas Packaging Systems business from 2012. Prior to this, she held a number of positions of increasing responsibility in technical, marketing and sales roles.
Ms. Flynn serves on the board of Quanterix Corporation (NASDAQ:QTRX), Sotera Health (NASDAQ: SHC), and a privately held company. She previously served on the boards of Recro Pharmaceuticals (NASDAQ:SCTL) from September 2015 to January 2020 and Catalent (NYSE:CTLT) from September 2022 to January 2024. She serves on the Board of Trustees for the Franklin Institute. Ms. Flynn holds a Master of Science in Business Administration from Boston University and a Master of Science in Engineering from the University of Pennsylvania. She received her Bachelor of Science in Pre-Professional Studies from the University of Notre Dame.
She has been a member of the board of directors of Stevanato Group since 2024.
Donald Eugene Morel Jr.

Donald Eugene Morel Jr.

Dr. Morel served as Chief Executive Officer of West from 2002 through 2015 and Chairman from 2003-2015. During his tenure revenues tripled and market capitalization increased more than twelve times. West was the top performing healthcare dividend stock on the NYSE over this time period. Prior to being named CEO he served as Chief Operating Officer and President of the Pharmaceutical Systems Division. His career at West started in 1992 as Director of R&D. From 1984 to 1992 he worked in various positions developing technology for space based remote imaging and the Strategic Defense Initiative. He served as an advisor to NASA on a number of Space Station programs and in 1989 was selected by the Astronaut Office for training as a Mission Specialist. His research has been funded by NASA, the Office of Naval Research, the National Science Foundation, and DARPA. Dr. Morel completed his undergraduate degree in Engineering at Lafayette College and his graduate studies at Cornell University in Materials Science and Veterinary Medicine and the Darden School of the University of Virginia. He received a D.Sc. (Hons) from Roanoke College. Dr. Morel serves as a Director of Catalent Corporation (NYSE: CTLT), and the Stevanato Group SpA (NYSE:STVN). He is Chairman Emeritus of the Board of Trustees of the Franklin Institute in Philadelphia, PA and also chairs the Foundation Board of the American Oncologic Hospital of the Fox Chase Cancer Center. He is the founder of Progenitor Capital LLC and Chairs the Morel Family Foundation. He has been a member of the board of directors of Stevanato Group since 2018.

Franco Moro

Franco Moro

Graduating in Chemical Engineering from the University of Padua in 1987, and holding an MBA from SDA Bocconi in Milan, Franco has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS—Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS—Fabbrica Italiana Sintetici from 2010 to 2018. Franco joined Stevanato Group in 2019 as Chief Operating Officer and was appointed to Chief Executive Officer in February 2021 and served until May 2024. He has been a member of the board of directors of Stevanato Group since February 2021.

Luciano Santel

Luciano Santel

After graduating in Business Administration at University Ca' Foscari of Venice, he spent his early years in international audit companies like Ernst & Young and Arthur Andersen.
He worked as Finance Director at IVG and then at Rossignol group. In 1996 he became Chief Operating Officer of Retail Brand Alliance (already Casual Corner group Inc.) where he remained until 1999 when he joined Luxottica Group S.p.A. as Vice President International Development. From 2001 to 2009 he was Chief Corporate Officer at Geox S.p.A., whilst in 2009 he became Chief Executive Officer for Stefanel S.p.A. He also served as an Independent Director of Luxottica Group S.p.A. from 2015 to 2020.
In 2013 he joined Moncler as Chief Corporate Officer. He is currently Executive Director of Moncler and Chief Corporate & Supply Officer of the Moncler Group; he is also Manager in Charge pursuant to Article 154-bis of the Consolidated Law on Finance.
He has been a member of the board of directors of Stevanato Group since 2024.
Alvise Spinazzi

Alvise Spinazzi

Graduated in Law from the University of Padua in 1997, he obtained an LL.M. in International Business and Trade Law from Fordham University School of Law in New York. He qualified as a lawyer in New York in 2000 and in Italy in 2001. A founding member of the law firm SAT Studio Legale in Padua in 2007, Alvise also practiced in the New York office of the international law firm Simpson Thacher & Bartlett and in the Milan office of Italian law firm Chiomenti. He has been a member of the board of directors of Stevanato Group since 2011.

Paola Vezzaro

Paola Vezzaro

Graduated in Business Administration from the University Commerciale “Luigi Bocconi” in Milan, a B.S. in Political Science and Sociology from the University of Milan. and a M.S. in Human Resources from Cattolica University in Milan, Paola, brings extensive experience in human resources management having served as HR director in many primary companies. She joined Engie in 2011, where she has held several international management positions. Since July 2019, she has served as Chief Human Resources and Health & Safety Officer North, South and Eastern Europe for Engie. She has been a member of the board of directors of Stevanato Group since May 2021.